10-K Filing

REGENERON PHARMACEUTICALS, INC. CIK: 872589 FY 2016

Filing Information

Form Type	10-K
Accession Number	`0001532176-17-000008`
Period End Date	20161231
Filing Date	20170209
Fiscal Year	2016
Fiscal Period	FY
XBRL Instance	regn-20161231.xml

Filing Contents

This filing contains the following financial statements:

Balance Sheet 78 Income Statement 112 Cash Flow Statement 94 Stockholders Equity 53

Balance Sheet 78 line items

Line Item	Tag	Value	Unit	Period
Preferred stock, par value (in dollars per share)	`PreferredStockParOrStatedValuePerShare`	$0.01	USD	Point-in-time
Preferred stock, par value (in dollars per share)	`PreferredStockParOrStatedValuePerShare`	$0.01	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$535.20M	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$535.61M	USD	Point-in-time
Preferred stock, shares authorized (in shares)	`PreferredStockSharesAuthorized`	30.00M	shares	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$809.10M	USD	Point-in-time
Preferred stock, shares authorized (in shares)	`PreferredStockSharesAuthorized`	30.00M	shares	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$648.72M	USD	Point-in-time
Marketable securities	`MarketableSecuritiesCurrent`	$503.48M	USD	Point-in-time
Preferred stock, shares issued (in shares)	`PreferredStockSharesIssued`	0.00	shares	Point-in-time
Preferred stock, shares issued (in shares)	`PreferredStockSharesIssued`	0.00	shares	Point-in-time
Marketable securities	`MarketableSecuritiesCurrent`	$236.12M	USD	Point-in-time
Accounts receivable - trade, net	`AccountsReceivableNetCurrent`	$1.34B	USD	Point-in-time
Accounts receivable - trade, net	`AccountsReceivableNetCurrent`	$1.15B	USD	Point-in-time
Preferred stock, shares outstanding (in shares)	`PreferredStockSharesOutstanding`	0.00	shares	Point-in-time
Preferred stock, shares outstanding (in shares)	`PreferredStockSharesOutstanding`	0.00	shares	Point-in-time
Accounts receivable from Sanofi	`AccountsReceivableRelatedPartiesCurrent`	$92.99M	USD	Point-in-time
Treasury stock, shares outstanding (in shares)	`TreasuryStockShares`	3.64M	shares	Point-in-time
Treasury stock, shares outstanding (in shares)	`TreasuryStockShares`	3.76M	shares	Point-in-time
Accounts receivable from Sanofi	`AccountsReceivableRelatedPartiesCurrent`	$153.15M	USD	Point-in-time
Accounts receivable from Bayer HealthCare	`AccountsAndNotesReceivableNet`	$162.15M	USD	Point-in-time
Accounts receivable from Bayer HealthCare	`AccountsAndNotesReceivableNet`	$175.26M	USD	Point-in-time
Inventories	`InventoryNet`	$399.36M	USD	Point-in-time
Inventories	`InventoryNet`	$238.58M	USD	Point-in-time
Prepaid expenses and other current assets	`PrepaidExpenseAndOtherAssetsCurrent`	$130.53M	USD	Point-in-time
Prepaid expenses and other current assets	`PrepaidExpenseAndOtherAssetsCurrent`	$163.50M	USD	Point-in-time
Total current assets	`AssetsCurrent`	$3.18B	USD	Point-in-time
Total current assets	`AssetsCurrent`	$2.92B	USD	Point-in-time
Marketable securities	`MarketableSecuritiesNoncurrent`	$864.26M	USD	Point-in-time
Marketable securities	`MarketableSecuritiesNoncurrent`	$632.16M	USD	Point-in-time
Property, plant, and equipment, net	`PropertyPlantAndEquipmentNet`	$1.59B	USD	Point-in-time
Property, plant, and equipment, net	`PropertyPlantAndEquipmentNet`	$2.08B	USD	Point-in-time
Deferred tax assets	`DeferredTaxAssetsLiabilitiesNetNoncurrent`	$461.94M	USD	Point-in-time
Deferred tax assets	`DeferredTaxAssetsLiabilitiesNetNoncurrent`	$825.30M	USD	Point-in-time
Other assets	`OtherAssetsNoncurrent`	$5.81M	USD	Point-in-time
Other assets	`OtherAssetsNoncurrent`	$20.29M	USD	Point-in-time
Total assets	`Assets`	$5.61B	USD	Point-in-time
Total assets	`Assets`	$6.97B	USD	Point-in-time
Accounts payable and accrued expenses	`AccountsPayableAndAccruedLiabilitiesCurrent`	$879.10M	USD	Point-in-time
Accounts payable and accrued expenses	`AccountsPayableAndAccruedLiabilitiesCurrent`	$644.11M	USD	Point-in-time
Capital Lease Obligations	`CapitalLeaseObligationsCurrent`	$127.27M	USD	Point-in-time
Capital Lease Obligations	`CapitalLeaseObligationsCurrent`	-	USD	Point-in-time
Deferred revenue from Sanofi, current portion	`DeferredRevenueFromRelatedPartyCurrent`	$101.57M	USD	Point-in-time
Deferred revenue from Sanofi, current portion	`DeferredRevenueFromRelatedPartyCurrent`	$115.27M	USD	Point-in-time
Deferred revenue - other, current portion	`DeferredRevenueExcludingAmountsFromRelatedPartyCurrent`	$51.91M	USD	Point-in-time
Deferred revenue - other, current portion	`DeferredRevenueExcludingAmountsFromRelatedPartyCurrent`	$116.40M	USD	Point-in-time
Other current liabilities	`OtherLiabilitiesCurrent`	$13.56M	USD	Point-in-time
Other current liabilities	`OtherLiabilitiesCurrent`	$3.46M	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$1.24B	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$811.16M	USD	Point-in-time
Deferred revenue from Sanofi	`DeferredRevenueFromRelatedPartyNoncurrent`	$503.47M	USD	Point-in-time
Deferred revenue from Sanofi	`DeferredRevenueFromRelatedPartyNoncurrent`	$582.66M	USD	Point-in-time
Deferred revenue - other	`DeferredRevenueExcludingAmountsFromRelatedPartyNonCurrent`	$327.30M	USD	Point-in-time
Deferred revenue - other	`DeferredRevenueExcludingAmountsFromRelatedPartyNonCurrent`	$82.02M	USD	Point-in-time
Facility lease obligations	`FacilityLeaseObligationsNoncurrent`	$351.57M	USD	Point-in-time
Facility lease obligations	`FacilityLeaseObligationsNoncurrent`	$362.92M	USD	Point-in-time
Other long term liabilities	`OtherLiabilitiesNoncurrent`	$115.53M	USD	Point-in-time
Other long term liabilities	`OtherLiabilitiesNoncurrent`	$100.39M	USD	Point-in-time
Total liabilities	`Liabilities`	$1.95B	USD	Point-in-time
Total liabilities	`Liabilities`	$2.52B	USD	Point-in-time
Commitments and contingencies (Note 12)	`CommitmentsAndContingencies`	-	USD	Point-in-time
Commitments and contingencies (Note 12)	`CommitmentsAndContingencies`	-	USD	Point-in-time
Preferred Stock	`PreferredStockValue`	-	USD	Point-in-time
Preferred Stock	`PreferredStockValue`	-	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapital`	$3.10B	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapital`	$3.03B	USD	Point-in-time
Retained earnings	`RetainedEarningsAccumulatedDeficit`	$1.75B	USD	Point-in-time
Retained earnings	`RetainedEarningsAccumulatedDeficit`	$852.70M	USD	Point-in-time
Accumulated other comprehensive (loss) income	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	$-12.84M	USD	Point-in-time
Accumulated other comprehensive (loss) income	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	$8.57M	USD	Point-in-time
Treasury Stock	`TreasuryStockValue`	$316.24M	USD	Point-in-time
Treasury Stock	`TreasuryStockValue`	$306.07M	USD	Point-in-time
Total stockholders' equity	`StockholdersEquity`	$2.55B	USD	Point-in-time
Total stockholders' equity	`StockholdersEquity`	$3.65B	USD	Point-in-time
Total stockholders' equity	`StockholdersEquity`	$1.96B	USD	Point-in-time
Total stockholders' equity	`StockholdersEquity`	$4.45B	USD	Point-in-time
Total liabilities and stockholders' equity	`LiabilitiesAndStockholdersEquity`	$6.97B	USD	Point-in-time
Total liabilities and stockholders' equity	`LiabilitiesAndStockholdersEquity`	$5.61B	USD	Point-in-time

Income Statement 112 line items

Line Item	Tag	Value	Unit	Period
Net product sales	`SalesRevenueGoodsNet`	$3.34B	USD	Annual
Net product sales	`SalesRevenueGoodsNet`	$1.75B	USD	Annual
Net product sales	`SalesRevenueGoodsNet`	$2.69B	USD	Annual
Sanofi collaboration revenue	`RevenueFromRelatedParties`	$758.87M	USD	Annual
Sanofi collaboration revenue	`RevenueFromRelatedParties`	$541.30M	USD	Annual
Sanofi collaboration revenue	`RevenueFromRelatedParties`	$658.66M	USD	Annual
Bayer collaboration revenue	`OtherCollaborationRevenue`	$580.49M	USD	Annual
Bayer collaboration revenue	`OtherCollaborationRevenue`	$495.56M	USD	Annual
Bayer collaboration revenue	`OtherCollaborationRevenue`	$744.27M	USD	Annual
Other revenue	`OtherSalesRevenueNet`	$74.89M	USD	Annual
Other revenue	`OtherSalesRevenueNet`	$31.94M	USD	Annual
Other revenue	`OtherSalesRevenueNet`	$119.10M	USD	Annual
Total revenues	`Revenues`	$2.82B	USD	Annual
Total revenues	`Revenues`	$4.10B	USD	Annual
Total revenues	`Revenues`	$1.23B	USD	1 Quarter
Total revenues	`Revenues`	$1.20B	USD	1 Quarter
Total revenues	`Revenues`	$869.61M	USD	1 Quarter
Total revenues	`Revenues`	$1.14B	USD	1 Quarter
Total revenues	`Revenues`	$998.62M	USD	1 Quarter
Total revenues	`Revenues`	$1.22B	USD	1 Quarter
Total revenues	`Revenues`	$1.21B	USD	1 Quarter
Total revenues	`Revenues`	$1.10B	USD	1 Quarter
Total revenues	`Revenues`	$4.86B	USD	Annual
Research and development	`ResearchAndDevelopmentExpense`	$1.27B	USD	Annual
Research and development	`ResearchAndDevelopmentExpense`	$1.62B	USD	Annual
Research and development	`ResearchAndDevelopmentExpense`	$2.05B	USD	Annual
Selling, general, and administrative	`SellingGeneralAndAdministrativeExpense`	$519.27M	USD	Annual
Selling, general, and administrative	`SellingGeneralAndAdministrativeExpense`	$838.53M	USD	Annual
Selling, general, and administrative	`SellingGeneralAndAdministrativeExpense`	$1.18B	USD	Annual
Cost of goods sold	`CostOfGoodsSold`	$194.62M	USD	Annual
Cost of goods sold	`CostOfGoodsSold`	$129.03M	USD	Annual
Cost of goods sold	`CostOfGoodsSold`	$241.70M	USD	Annual
Cost of collaboration and contract manufacturing	`Costofmanufacturing`	$105.07M	USD	Annual
Cost of collaboration and contract manufacturing	`Costofmanufacturing`	$75.99M	USD	Annual
Cost of collaboration and contract manufacturing	`Costofmanufacturing`	$151.01M	USD	Annual
Total expenses	`CostsAndExpenses`	$2.00B	USD	Annual
Total expenses	`CostsAndExpenses`	$2.85B	USD	Annual
Total expenses	`CostsAndExpenses`	$3.53B	USD	Annual
Income from operations	`OperatingIncomeLoss`	$1.25B	USD	Annual
Income from operations	`OperatingIncomeLoss`	$823.92M	USD	Annual
Income from operations	`OperatingIncomeLoss`	$1.33B	USD	Annual
Other income (expense), net	`OtherNonoperatingIncomeExpense`	$-25.31M	USD	Annual
Other income (expense), net	`OtherNonoperatingIncomeExpense`	$-12.58M	USD	Annual
Other income (expense), net	`OtherNonoperatingIncomeExpense`	$6.27M	USD	Annual
Interest expense	`InterestIncomeExpenseNonoperatingNet`	$-7.20M	USD	Annual
Interest expense	`InterestIncomeExpenseNonoperatingNet`	$-14.24M	USD	Annual
Interest expense	`InterestIncomeExpenseNonoperatingNet`	$-37.37M	USD	Annual
Total other income (expense)	`NonoperatingIncomeExpense`	$-926.00K	USD	Annual
Total other income (expense)	`NonoperatingIncomeExpense`	$-26.82M	USD	Annual
Total other income (expense)	`NonoperatingIncomeExpense`	$-62.68M	USD	Annual
Income before income taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments`	$1.23B	USD	Annual
Income before income taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments`	$761.24M	USD	Annual
Income before income taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments`	$1.33B	USD	Annual
Income tax expense	`IncomeTaxExpenseBenefit`	$434.29M	USD	Annual
Income tax expense	`IncomeTaxExpenseBenefit`	$423.11M	USD	Annual
Income tax expense	`IncomeTaxExpenseBenefit`	$589.04M	USD	Annual
Net income	`NetIncomeLoss`	$154.99M	USD	1 Quarter
Net income	`NetIncomeLoss`	$181.38M	USD	1 Quarter
Net income	`NetIncomeLoss`	$338.13M	USD	Annual
Net income	`NetIncomeLoss`	$196.22M	USD	1 Quarter
Net income	`NetIncomeLoss`	$76.02M	USD	1 Quarter
Net income	`NetIncomeLoss`	$895.52M	USD	Annual
Net income	`NetIncomeLoss`	$253.12M	USD	1 Quarter
Net income	`NetIncomeLoss`	$210.40M	USD	1 Quarter
Net income	`NetIncomeLoss`	$636.06M	USD	Annual
Net income	`NetIncomeLoss`	$264.80M	USD	1 Quarter
Net income	`NetIncomeLoss`	$194.64M	USD	1 Quarter
Net income per share - basic	`EarningsPerShareBasic`	$2.04	USD	1 Quarter
Net income per share - basic	`EarningsPerShareBasic`	$1.74	USD	1 Quarter
Net income per share - basic	`EarningsPerShareBasic`	$6.17	USD	Annual
Net income per share - basic	`EarningsPerShareBasic`	$1.89	USD	1 Quarter
Net income per share - basic	`EarningsPerShareBasic`	$2.41	USD	1 Quarter
Net income per share - basic	`EarningsPerShareBasic`	$8.55	USD	Annual
Net income per share - basic	`EarningsPerShareBasic`	$0.74	USD	1 Quarter
Net income per share - basic	`EarningsPerShareBasic`	$3.36	USD	Annual
Net income per share - basic	`EarningsPerShareBasic`	$1.49	USD	1 Quarter
Net income per share - basic	`EarningsPerShareBasic`	$2.53	USD	1 Quarter
Net income per share - basic	`EarningsPerShareBasic`	$1.88	USD	1 Quarter
Net income per share - diluted	`EarningsPerShareDiluted`	$1.82	USD	1 Quarter
Net income per share - diluted	`EarningsPerShareDiluted`	$1.59	USD	1 Quarter
Net income per share - diluted	`EarningsPerShareDiluted`	$1.69	USD	1 Quarter
Net income per share - diluted	`EarningsPerShareDiluted`	$7.70	USD	Annual
Net income per share - diluted	`EarningsPerShareDiluted`	$5.52	USD	Annual
Net income per share - diluted	`EarningsPerShareDiluted`	$2.98	USD	Annual
Net income per share - diluted	`EarningsPerShareDiluted`	$1.34	USD	1 Quarter
Net income per share - diluted	`EarningsPerShareDiluted`	$2.19	USD	1 Quarter
Net income per share - diluted	`EarningsPerShareDiluted`	$1.69	USD	1 Quarter
Net income per share - diluted	`EarningsPerShareDiluted`	$0.66	USD	1 Quarter
Net income per share - diluted	`EarningsPerShareDiluted`	$2.27	USD	1 Quarter
Weighted average shares outstanding - basic	`WeightedAverageNumberOfSharesOutstandingBasic`	104.72M	shares	Annual
Weighted average shares outstanding - basic	`WeightedAverageNumberOfSharesOutstandingBasic`	103.06M	shares	Annual
Weighted average shares outstanding - basic	`WeightedAverageNumberOfSharesOutstandingBasic`	100.61M	shares	Annual
Weighted average shares outstanding - diluted	`WeightedAverageNumberOfDilutedSharesOutstanding`	116.37M	shares	Annual
Weighted average shares outstanding - diluted	`WeightedAverageNumberOfDilutedSharesOutstanding`	113.41M	shares	Annual
Weighted average shares outstanding - diluted	`WeightedAverageNumberOfDilutedSharesOutstanding`	115.23M	shares	Annual
Net income	`NetIncomeLoss`	$154.99M	USD	1 Quarter
Net income	`NetIncomeLoss`	$181.38M	USD	1 Quarter
Net income	`NetIncomeLoss`	$338.13M	USD	Annual
Net income	`NetIncomeLoss`	$196.22M	USD	1 Quarter
Net income	`NetIncomeLoss`	$76.02M	USD	1 Quarter
Net income	`NetIncomeLoss`	$895.52M	USD	Annual
Net income	`NetIncomeLoss`	$253.12M	USD	1 Quarter
Net income	`NetIncomeLoss`	$210.40M	USD	1 Quarter
Net income	`NetIncomeLoss`	$636.06M	USD	Annual
Net income	`NetIncomeLoss`	$264.80M	USD	1 Quarter
Net income	`NetIncomeLoss`	$194.64M	USD	1 Quarter
Unrealized (loss) gain on marketable securities, net of tax	`OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax`	$-21.41M	USD	Annual
Unrealized (loss) gain on marketable securities, net of tax	`OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax`	$53.44M	USD	Annual
Unrealized (loss) gain on marketable securities, net of tax	`OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax`	$-43.68M	USD	Annual
Comprehensive income	`ComprehensiveIncomeNetOfTax`	$874.11M	USD	Annual
Comprehensive income	`ComprehensiveIncomeNetOfTax`	$592.38M	USD	Annual
Comprehensive income	`ComprehensiveIncomeNetOfTax`	$391.56M	USD	Annual

Cash Flow Statement 94 line items

Line Item	Tag	Value	Unit	Period
Net income	`NetIncomeLoss`	$154.99M	USD	1 Quarter
Net income	`NetIncomeLoss`	$181.38M	USD	1 Quarter
Net income	`NetIncomeLoss`	$338.13M	USD	Annual
Net income	`NetIncomeLoss`	$196.22M	USD	1 Quarter
Net income	`NetIncomeLoss`	$76.02M	USD	1 Quarter
Net income	`NetIncomeLoss`	$895.52M	USD	Annual
Net income	`NetIncomeLoss`	$253.12M	USD	1 Quarter
Net income	`NetIncomeLoss`	$210.40M	USD	1 Quarter
Net income	`NetIncomeLoss`	$636.06M	USD	Annual
Net income	`NetIncomeLoss`	$264.80M	USD	1 Quarter
Net income	`NetIncomeLoss`	$194.64M	USD	1 Quarter
Depreciation and amortization	`DepreciationDepletionAndAmortization`	$104.75M	USD	Annual
Depreciation and amortization	`DepreciationDepletionAndAmortization`	$52.69M	USD	Annual
Depreciation and amortization	`DepreciationDepletionAndAmortization`	$74.91M	USD	Annual
Non-cash compensation expense	`ShareBasedCompensation`	$321.75M	USD	Annual
Non-cash compensation expense	`ShareBasedCompensation`	$459.05M	USD	Annual
Non-cash compensation expense	`ShareBasedCompensation`	$559.88M	USD	Annual
Other non-cash charges and expenses, net	`OtherNoncashIncomeExpense`	$-77.57M	USD	Annual
Other non-cash charges and expenses, net	`OtherNoncashIncomeExpense`	$-45.14M	USD	Annual
Other non-cash charges and expenses, net	`OtherNoncashIncomeExpense`	$-52.56M	USD	Annual
Deferred Taxes	`IncreaseDecreaseInDeferredIncomeTaxes`	$53.28M	USD	Annual
Deferred Taxes	`IncreaseDecreaseInDeferredIncomeTaxes`	$121.62M	USD	Annual
Deferred Taxes	`IncreaseDecreaseInDeferredIncomeTaxes`	$360.08M	USD	Annual
Increase in Sanofi, Bayer, and trade accounts receivable	`IncreaseDecreaseInAccountsReceivable`	$491.42M	USD	Annual
Increase in Sanofi, Bayer, and trade accounts receivable	`IncreaseDecreaseInAccountsReceivable`	$34.93M	USD	Annual
Increase in Sanofi, Bayer, and trade accounts receivable	`IncreaseDecreaseInAccountsReceivable`	$143.83M	USD	Annual
Increase in Inventories	`IncreaseDecreaseInInventories`	$149.78M	USD	Annual
Increase in Inventories	`IncreaseDecreaseInInventories`	$56.95M	USD	Annual
Increase in Inventories	`IncreaseDecreaseInInventories`	$111.83M	USD	Annual
Decrease (increase) in prepaid expenses and other assets	`IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets`	$79.48M	USD	Annual
Decrease (increase) in prepaid expenses and other assets	`IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets`	$45.33M	USD	Annual
Decrease (increase) in prepaid expenses and other assets	`IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets`	$-23.54M	USD	Annual
Increase (decrease) in deferred revenue	`IncreaseDecreaseInDeferredRevenue`	$-8.40M	USD	Annual
Increase (decrease) in deferred revenue	`IncreaseDecreaseInDeferredRevenue`	$608.89M	USD	Annual
Increase (decrease) in deferred revenue	`IncreaseDecreaseInDeferredRevenue`	$244.27M	USD	Annual
Increase in accounts payable, accrued expenses and other liabilities	`IncreaseDecreaseInAccountsPayableAndAccruedLiabilities`	$303.66M	USD	Annual
Increase in accounts payable, accrued expenses and other liabilities	`IncreaseDecreaseInAccountsPayableAndAccruedLiabilities`	$253.98M	USD	Annual
Increase in accounts payable, accrued expenses and other liabilities	`IncreaseDecreaseInAccountsPayableAndAccruedLiabilities`	$161.18M	USD	Annual
Total adjustments	`AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities`	$694.72M	USD	Annual
Total adjustments	`AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities`	$414.31M	USD	Annual
Total adjustments	`AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities`	$577.87M	USD	Annual
Net cash provided by operating activities	`NetCashProvidedByUsedInOperatingActivities`	$1.33B	USD	Annual
Net cash provided by operating activities	`NetCashProvidedByUsedInOperatingActivities`	$1.47B	USD	Annual
Net cash provided by operating activities	`NetCashProvidedByUsedInOperatingActivities`	$752.43M	USD	Annual
Purchases of marketable securities	`PaymentsToAcquireMarketableSecurities`	$809.42M	USD	Annual
Purchases of marketable securities	`PaymentsToAcquireMarketableSecurities`	$564.19M	USD	Annual
Purchases of marketable securities	`PaymentsToAcquireMarketableSecurities`	$557.11M	USD	Annual
Sales or maturities of marketable securities	`ProceedsFromSaleAndMaturityOfMarketableSecurities`	$327.44M	USD	Annual
Sales or maturities of marketable securities	`ProceedsFromSaleAndMaturityOfMarketableSecurities`	$274.46M	USD	Annual
Sales or maturities of marketable securities	`ProceedsFromSaleAndMaturityOfMarketableSecurities`	$476.42M	USD	Annual
Capital expenditures	`PaymentsToAcquireProductiveAssets`	$333.01M	USD	Annual
Capital expenditures	`PaymentsToAcquireProductiveAssets`	$511.94M	USD	Annual
Capital expenditures	`PaymentsToAcquireProductiveAssets`	$677.93M	USD	Annual
Net cash used in by investing activities	`NetCashProvidedByUsedInInvestingActivities`	$-907.60M	USD	Annual
Net cash used in by investing activities	`NetCashProvidedByUsedInInvestingActivities`	$-420.78M	USD	Annual
Net cash used in by investing activities	`NetCashProvidedByUsedInInvestingActivities`	$-1.05B	USD	Annual
(Payments) proceeds in connection with capital and facility lease obligations	`ProceedsFromRepaymentsOfLongTermDebtAndCapitalSecurities`	$26.02M	USD	Annual
(Payments) proceeds in connection with capital and facility lease obligations	`ProceedsFromRepaymentsOfLongTermDebtAndCapitalSecurities`	$-1.09M	USD	Annual
(Payments) proceeds in connection with capital and facility lease obligations	`ProceedsFromRepaymentsOfLongTermDebtAndCapitalSecurities`	$-27.69M	USD	Annual
Repayments of convertible senior notes	`RepaymentsOfConvertibleDebt`	$220.64M	USD	Annual
Repayments of convertible senior notes	`RepaymentsOfConvertibleDebt`	$12.89M	USD	Annual
Repayments of convertible senior notes	`RepaymentsOfConvertibleDebt`	$166.47M	USD	Annual
Payments in connection with reduction of outstanding warrants	`PaymentsForRepurchaseOfWarrants`	$643.37M	USD	Annual
Payments in connection with reduction of outstanding warrants	`PaymentsForRepurchaseOfWarrants`	$573.49M	USD	Annual
Payments in connection with reduction of outstanding warrants	`PaymentsForRepurchaseOfWarrants`	$294.55M	USD	Annual
Proceeds from issuance of Common Stock	`ProceedsFromIssuanceOfCommonStock`	$206.36M	USD	Annual
Proceeds from issuance of Common Stock	`ProceedsFromIssuanceOfCommonStock`	$126.05M	USD	Annual
Proceeds from issuance of Common Stock	`ProceedsFromIssuanceOfCommonStock`	$126.74M	USD	Annual
Payments in connection with Common Stock tendered for employee tax obligations	`PaymentsRelatedToTaxWithholdingForShareBasedCompensation`	$267.58M	USD	Annual
Payments in connection with Common Stock tendered for employee tax obligations	`PaymentsRelatedToTaxWithholdingForShareBasedCompensation`	$143.18M	USD	Annual
Payments in connection with Common Stock tendered for employee tax obligations	`PaymentsRelatedToTaxWithholdingForShareBasedCompensation`	$160.54M	USD	Annual
Excess tax benefit from stock-based compensation	`ExcessTaxBenefitFromShareBasedCompensationFinancingActivities`	$405.32M	USD	Annual
Excess tax benefit from stock-based compensation	`ExcessTaxBenefitFromShareBasedCompensationFinancingActivities`	-	USD	Annual
Excess tax benefit from stock-based compensation	`ExcessTaxBenefitFromShareBasedCompensationFinancingActivities`	$439.28M	USD	Annual
Net cash (used in) provided by financing activities	`NetCashProvidedByUsedInFinancingActivities`	$-262.80M	USD	Annual
Net cash (used in) provided by financing activities	`NetCashProvidedByUsedInFinancingActivities`	$-700.39M	USD	Annual
Net cash (used in) provided by financing activities	`NetCashProvidedByUsedInFinancingActivities`	$-218.55M	USD	Annual
Net (decrease) increase in cash and cash equivalents	`CashAndCashEquivalentsPeriodIncreaseDecrease`	$160.38M	USD	Annual
Net (decrease) increase in cash and cash equivalents	`CashAndCashEquivalentsPeriodIncreaseDecrease`	$-273.90M	USD	Annual
Net (decrease) increase in cash and cash equivalents	`CashAndCashEquivalentsPeriodIncreaseDecrease`	$113.11M	USD	Annual
Cash and cash equivalents at beginning of period	`CashAndCashEquivalentsAtCarryingValue`	$535.20M	USD	Point-in-time
Cash and cash equivalents at beginning of period	`CashAndCashEquivalentsAtCarryingValue`	$535.61M	USD	Point-in-time
Cash and cash equivalents at beginning of period	`CashAndCashEquivalentsAtCarryingValue`	$809.10M	USD	Point-in-time
Cash and cash equivalents at beginning of period	`CashAndCashEquivalentsAtCarryingValue`	$648.72M	USD	Point-in-time
Cash and cash equivalents at end of period	`CashAndCashEquivalentsAtCarryingValue`	$535.20M	USD	Point-in-time
Cash and cash equivalents at end of period	`CashAndCashEquivalentsAtCarryingValue`	$535.61M	USD	Point-in-time
Cash and cash equivalents at end of period	`CashAndCashEquivalentsAtCarryingValue`	$809.10M	USD	Point-in-time
Cash and cash equivalents at end of period	`CashAndCashEquivalentsAtCarryingValue`	$648.72M	USD	Point-in-time
Cash paid for interest (net of amounts capitalized)	`InterestPaidNet`	$5.45M	USD	Annual
Cash paid for interest (net of amounts capitalized)	`InterestPaidNet`	$20.35M	USD	Annual
Cash paid for interest (net of amounts capitalized)	`InterestPaidNet`	$10.58M	USD	Annual
Cash paid for income taxes	`IncomeTaxesPaidNet`	$59.85M	USD	Annual
Cash paid for income taxes	`IncomeTaxesPaidNet`	$481.36M	USD	Annual
Cash paid for income taxes	`IncomeTaxesPaidNet`	$276.09M	USD	Annual

Stockholders Equity 53 line items

Line Item	Tag	Value	Unit	Period
Balance	`StockholdersEquity`	$2.55B	USD	Point-in-time
Balance	`StockholdersEquity`	$3.65B	USD	Point-in-time
Balance	`StockholdersEquity`	$1.96B	USD	Point-in-time
Balance	`StockholdersEquity`	$4.45B	USD	Point-in-time
Issuance of Common Stock in connection with exercise of stock options	`StockIssuedDuringPeriodValueStockOptionsExercised`	$115.18M	USD	Annual
Issuance of Common Stock in connection with exercise of stock options	`StockIssuedDuringPeriodValueStockOptionsExercised`	$215.46M	USD	Annual
Issuance of Common Stock in connection with exercise of stock options	`StockIssuedDuringPeriodValueStockOptionsExercised`	$125.90M	USD	Annual
Common Stock tendered upon exercise of stock options in connection with employee tax obligations	`AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation`	$143.18M	USD	Annual
Common Stock tendered upon exercise of stock options in connection with employee tax obligations	`AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation`	$160.54M	USD	Annual
Common Stock tendered upon exercise of stock options in connection with employee tax obligations	`AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation`	$267.58M	USD	Annual
Issuance of Common Stock in connection with conversion of convertible senior notes	`StockIssuedDuringPeriodValueConversionOfConvertibleSecurities`	$818.36M	USD	Annual
Issuance of Common Stock in connection with conversion of convertible senior notes	`StockIssuedDuringPeriodValueConversionOfConvertibleSecurities`	$48.00M	USD	Annual
Issuance of Common Stock in connection with conversion of convertible senior notes	`StockIssuedDuringPeriodValueConversionOfConvertibleSecurities`	$691.36M	USD	Annual
Issuance of Common Stock in connection with Company 401(k) Savings Plan contribution	`StockIssuedDuringPeriodValueEmployeeBenefitPlan`	$16.56M	USD	Annual
Issuance of Common Stock in connection with Company 401(k) Savings Plan contribution	`StockIssuedDuringPeriodValueEmployeeBenefitPlan`	$13.12M	USD	Annual
Issuance of Common Stock in connection with Company 401(k) Savings Plan contribution	`StockIssuedDuringPeriodValueEmployeeBenefitPlan`	$15.38M	USD	Annual
Issuance of restricted Common Stock under Long-Term Incentive Plan	`StockIssuedDuringPeriodValueRestrictedStockAwardGross`	-	USD	Annual
Issuance of restricted Common Stock under Long-Term Incentive Plan	`StockIssuedDuringPeriodValueRestrictedStockAwardGross`	-	USD	Annual
Issuance of restricted Common Stock under Long-Term Incentive Plan	`StockIssuedDuringPeriodValueRestrictedStockAwardGross`	-	USD	Annual
Stock-based compensation charges	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$464.02M	USD	Annual
Stock-based compensation charges	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$326.81M	USD	Annual
Stock-based compensation charges	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$574.89M	USD	Annual
Excess tax benefit from stock-based compensation	`AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet`	$405.32M	USD	Annual
Excess tax benefit from stock-based compensation	`AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet`	$439.28M	USD	Annual
Acquisition of Common Stock in connection with exercise of convertible note hedges	`TreasuryStockValueAcquiredCostMethod`	-	USD	Annual
Acquisition of Common Stock in connection with exercise of convertible note hedges	`TreasuryStockValueAcquiredCostMethod`	-	USD	Annual
Acquisition of Common Stock in connection with exercise of convertible note hedges	`TreasuryStockValueAcquiredCostMethod`	-	USD	Annual
Reduction of warrants	`AdjustmentsToAdditionalPaidInCapitalOther`	$-643.37M	USD	Annual
Reduction of warrants	`AdjustmentsToAdditionalPaidInCapitalOther`	$-449.46M	USD	Annual
Reduction of warrants	`AdjustmentsToAdditionalPaidInCapitalOther`	$-294.55M	USD	Annual
Reclassification of warrant liability	`Maximumamountofwarrantpayable`	$148.50M	USD	Annual
Reclassification of warrant liability	`Maximumamountofwarrantpayable`	$-23.32M	USD	Annual
Reduction of equity component of convertible senior notes	`AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments`	$47.79M	USD	Annual
Reduction of equity component of convertible senior notes	`AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments`	$819.66M	USD	Annual
Reduction of equity component of convertible senior notes	`AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments`	$691.87M	USD	Annual
Net income	`NetIncomeLoss`	$154.99M	USD	1 Quarter
Net income	`NetIncomeLoss`	$181.38M	USD	1 Quarter
Net income	`NetIncomeLoss`	$338.13M	USD	Annual
Net income	`NetIncomeLoss`	$196.22M	USD	1 Quarter
Net income	`NetIncomeLoss`	$76.02M	USD	1 Quarter
Net income	`NetIncomeLoss`	$895.52M	USD	Annual
Net income	`NetIncomeLoss`	$253.12M	USD	1 Quarter
Net income	`NetIncomeLoss`	$210.40M	USD	1 Quarter
Net income	`NetIncomeLoss`	$636.06M	USD	Annual
Net income	`NetIncomeLoss`	$264.80M	USD	1 Quarter
Net income	`NetIncomeLoss`	$194.64M	USD	1 Quarter
Other comprehensive income (loss), net of tax	`OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax`	$-21.41M	USD	Annual
Other comprehensive income (loss), net of tax	`OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax`	$53.44M	USD	Annual
Other comprehensive income (loss), net of tax	`OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax`	$-43.68M	USD	Annual
Balance	`StockholdersEquity`	$2.55B	USD	Point-in-time
Balance	`StockholdersEquity`	$3.65B	USD	Point-in-time
Balance	`StockholdersEquity`	$1.96B	USD	Point-in-time
Balance	`StockholdersEquity`	$4.45B	USD	Point-in-time

Data is extracted from SEC EDGAR XBRL filings. Values shown are as reported in the filing.